Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.

Cutis

Ms. Chat is from the Medical College of Georgia at Augusta University. Dr. Uppal is from Albany Medical College, New York. Mr. Kearns is from Loma Linda University School of Medicine, California. Dr. Han is from the Icahn School of Medicine at Mount Sinai, New York, New York. Dr. Wu is from the Dermatology Research and Education Foundation, Irvine, California.

Published: February 2021

In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity, drug-related interactions, and contraindications alongside evidence-based treatment recommendations for each systemic therapy. Important considerations for treatment such as drug selection, initiation of therapy, drug monitoring, and patient management also are discussed. Physicians are encouraged to use these recommendations to guide treatments based on individual patient needs and disease characteristics.

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0177DOI Listing

Publication Analysis

Top Keywords

management psoriasis
8
translating 2020
4
2020 aad-npf
4
aad-npf guidelines
4
guidelines care
4
care management
4
psoriasis systemic
4
systemic nonbiologics
4
nonbiologics clinical
4
clinical practice
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!